CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,164 enrolled
Drug / intervention
Wearable Cardioverter Defibrillatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03319160
NCT03319160N/ACompleted

Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France

Zoll Medical Corporation·observational·Posted Oct 24, 2017·Updated Dec 9, 2024

In Brief

An observational study evaluating Wearable Cardioverter Defibrillator for Sudden Cardiac Death and 3 related conditions. Completed, enrolled 1,164 participants across 2 sites.

Detailed Summary

This post-market study is a prospective observational study evaluating the efficacy and safety of the LifeVest in real-life settings.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 24, 2017
Enrollment StartFeb 2, 2017
Primary CompletionSep 30, 2018
Study CompletionMar 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.7 years ago

Interventions

Wearable Cardioverter Defibrillatordevice

A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention